Since PD-L1 is expressed in tumor cells, as well as TAMs and antigen-presenting cells (APCs), to maintain the immunosuppressive microenvironment in cSCC [61], the anti-PD1 Ab cemiplimab is used for the treatment of locally advanced and metastatic cSCC [70,71]. The gene discussed is CD274; the disease is skin squamous cell carcinoma.